GYRE THERAPEUTICS, INC.
Close on Oct 19, 2026
- Market cap
- $612.88M
- P/E (TTM)
- –
- Dividend yield
- –
About Gyre Therapeutics
Pharmaceutical Preparations, SIC 2834
Gyre Therapeutics, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule therapies targeting organ fibrosis and inflammatory conditions. The company's commercial portfolio includes ETUARY (pirfenidone) and Etorel (nintedanib) for idiopathic pulmonary fibrosis and other interstitial lung disorders, as well as Contiva (avatrombopag) for thrombocytopenia associated with chronic liver disease. Its clinical pipeline features Hydronidone for liver fibrosis, along with candidates addressing acute liver failure, pulmonary arterial hypertension, and chronic obstructive pulmonary disease. Gyre supplies therapies to adult patients requiring specialized pulmonary, hepatologic, and hospital-based medical care.
The company maintains corporate headquarters in San Diego, California, and conducts operations across the United States and the People's Republic of China. Commercial operations and clinical development in China run through its majority indirectly owned subsidiary, Beijing Continent Pharmaceuticals Co., Ltd., which oversees clinical research across numerous domestic medical centers and partners with local contract manufacturers.
Summary of the business section of Gyre Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GYRE THERAPEUTICS, INC.
- Headquarters
- San Diego, CA
- Address
- 12730 High Bluff Drive, Suite 250 92130
- Phone
- (858) 284-0115
- Website
- gyretx.com
- Employees
- 618, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Grant Thornton Zhitong Certified Public Accountants LLP, Beijing, China
Stock & identifiers
- Ticker
- GYRE
- Exchange
- Nasdaq
- IPO date
- Apr 12, 2006
- Shares outstanding
- 112M, Aug 1, 2026
- Public float
- $72.60M, Jun 30, 2025
- Filer category
- Accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-15 reverse, Oct 31, 2023; 1-for-15 reverse, Mar 8, 2017; 1-for-15 reverse, Feb 13, 2017; 1-for-92 reverse, Nov 5, 2015; 1-for-7 reverse, Aug 21, 2015
- SEC CIK
- 1124105
- CUSIP
- 403783103
- ISIN
- US4037831033
- LEI
- 549300TE6BBPJ0S88K48
- EIN
- 56-2020050
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ying Luo | Chief Executive Officer, Director | 2,565,226 |
| Songjiang Ma | President, Director | 2,806,084 |
| Weiguo Ye | Chief Operating Officer | 700,000 |
| Joshua Benjamin Bergmann | GC and Corporate Secretary | – |
| Jialiang (NMN) Wang | EVP, General Manager | – |
| Yue Xiong | Chief Scientific Officer | – |
| Thomas Wilson Eastling | Chief Financial Officer | 15,000 |
| Ruoyu Chen | Chief Financial Officer | – |
| Maxwell Kirkby | Director | – |
| Claire Weston | Director | – |
| Renate Parry | Director | – |
| Rodney L. Nussbaum | Director | – |
| Dan Weng | Director | – |
| Ping Zhang | Director | – |
| Gordon Carmichael | Director | – |
| David M. Epstein | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Han Ying Ph D | $353.32K | -$1.14M | $2.65M | $89 | – |
| FY2025 Ping Zhang | $4.10M | $2.89M | $2.65M | $89 | – |
| FY2024 Charles Wu Ph D | $15.35K | $15.35K | $491.57K | $134 | – |
| FY2024 Han Ying Ph D | $2.89M | $3.67M | $491.57K | $134 | – |
| FY2023 Charles Wu Ph D | $106.15K | $1.18M | $241.39K | $398 | – |
| FY2023 Songjiang Ma | $103.03K | $28.85M | $241.39K | $398 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 618 total employees, including 172 employees in Beijing, 43 employees in Cangzhou and 403 employees in other regions, which were primarily our sales and marketing employees located across the nation.”
Corporate history
Events identified from SEC filings